Dipòsit Digital de Documents de la UAB 15 registres trobats  1 - 10següent  anar al registre: La cerca s'ha fet en 0.00 segons. 
1.
7 p, 434.6 KB SCOT : a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer / Robles-Zurita, José (University of Glasgow. Institute of Health and Wellbeing) ; Boyd, Kathleen A. (University of Glasgow. Institute of Health and Wellbeing) ; Briggs, Andrew H. (University of Glasgow. Institute of Health and Wellbeing) ; Iveson, Timothy (Southampton University Hospital NHS Foundation Trust) ; Kerr, Rachel S. (University of Oxford. Department of Oncology) ; Saunders, Mark P. (The Christie Hospital) ; Cassidy, Jim (University of Glasgow. Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences) ; Hollander, Niels Henrik (Zealand University Hospital, Department of Oncology and Palliative Care, Rǻdmandsengen 5) ; Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ; Segelov, Eva (Australasian Gastro-Intestinal Trials Group (AGITG) and Monash University and Monash Health) ; Glimelius, Bengt (University of Uppsala) ; Harkin, Andrea (University of Glasgow. Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences) ; Allan, Karen (University of Glasgow. Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences) ; McQueen, John (University of Glasgow. Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences) ; Pearson, Sarah (University of Oxford. Department of Oncology, OCTO) ; Waterston, Ashita (Beatson West of Scotland Cancer Centre) ; Medley, Louise (Royal United Hospital) ; Wilson, Charles (Addenbrookes Hospital) ; Ellis, Richard (Royal Cornwall Hospitals NHS Trust) ; Essapen, Sharadah (St Luke's Cancer Centre, Royal Surrey County Hospital NHS Foundation Trust) ; Dhadda, Amandeep S. (Castle Hill Hospital) ; Hughes, Rob (Mount Vernon Cancer Centre) ; Falk, Stephen (Bristol Cancer Institute, Bristol, UK) ; Raouf, Sherif (Barking Havering and Redbridge University Hospital NHS Trust, Barking, UK) ; Rees, Charlotte (Southampton University Hospital NHS Foundation Trust) ; Olesen, Rene K (Zealand University Hospital, Department of Oncology and Palliative Care, Rǻdmandsengen 5) ; Propper, David (Queen Mary, University of London. Barts Cancer Institute) ; Bridgewater, John (University College London) ; Azzabi, Ashraf (Newcastle upon Tyne Hospitals NHS Foundation Trust) ; Farrugia, David (Gloucestershire Oncology Centre, Cheltenham General Hospital) ; Webb, Andrew (Brighton and Sussex University Hospital Trust) ; Cunningham, David (Royal Marsden (funded by NIHR BRC at the Royal Marsden)) ; Hickish, Tamas (Poole Hospital/Bournemouth University) ; Weaver, Andrew (Churchill Hospital, Oxford University Hospitals Foundation Trust) ; Gollins, Simon (North Wales Cancer Treatment Centre, Rhyl, UK) ; Wasan, Harpreet S (Hammersmith Hospital, Imperial College London) ; Paul, James (University of Glasgow. Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences)
The Short Course Oncology Therapy (SCOT) study is an international, multicentre, non-inferiority randomised controlled trial assessing the efficacy, toxicity, and cost-effectiveness of 3 months (3 M) versus the usually given 6 months (6 M) of adjuvant chemotherapy in colorectal cancer. [...]
2018 - 10.1038/s41416-018-0319-z
British Journal of Cancer, Vol. 119 (november 2018) , p. 1332-1338  
2.
9 p, 652.1 KB ASPN and GJB2 are implicated in the mechanisms of invasion of ductal breast carcinomas / Castellana, Bàrbara (Institut d'Investigació Biomèdica Sant Pau) ; Escuin, Daniel (Institut d'Investigació Biomèdica Sant Pau) ; Peiró, Gloria (Hospital General Universitario de Alicante) ; Garcia Valdecasas, Bárbara (Universitat Autònoma de Barcelona) ; Vázquez, Tania (Institut d'Investigació Biomèdica Sant Pau) ; Pons, Cristina (Institut d'Investigació Biomèdica Sant Pau) ; Pérez Olabarria, Maitane (Institut d'Investigació Biomèdica Sant Pau) ; Barnadas i Molins, Agustí (Universitat Autònoma de Barcelona. Departament de Medicina) ; Lerma Puertas, Enrique (Universitat Autònoma de Barcelona. Departament de Ciències Morfològiques)
The mechanism of progression from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) remains largely unknown. We compared gene expression in tumors with simultaneous DCIS and IDC to decipher how diverse proteins participate in the local invasive process. [...]
2012 - 10.7150/jca.4120
Journal of Cancer, Vol. 3, Núm. 1 (2012) , p. 175-183  
3.
11 p, 1.5 MB Mechanisms of inactivation of the tumour suppressor gene RHOA in colorectal cancer / Dopeso, Higinio (Vall d'Hebron Institut de Recerca) ; Rodrigues, Paulo (Vall d'Hebron Institut de Recerca) ; Bilic, Josipa (Vall d'Hebron Institut de Recerca) ; Bazzocco, Sarah (Vall d'Hebron Institut de Recerca) ; Cartón-García, Fernando (Vall d'Hebron Institut de Recerca) ; Macaya, Irati (Vall d'Hebron Institut de Recerca) ; de Marcondes, Priscila Guimarães (Vall d'Hebron Institut de Recerca) ; Anguita, Estefanía (Vall d'Hebron Institut de Recerca) ; Masanas, Marc (Vall d'Hebron Institut de Recerca) ; Jiménez-Flores, Lizbeth M (Vall d'Hebron Institut de Recerca) ; Martínez-Barriocanal, Águeda (Vall d'Hebron Institut de Recerca) ; Nieto, Rocío (Vall d'Hebron Institut de Recerca) ; Segura, Miguel F (Vall d'Hebron Institut de Recerca) ; Schwartz Jr, Simo (CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN)) ; Mariadason, John M (La Trobe University School of Cancer Medicine, Olivia Newton-John Cancer Research Institute) ; Arango, Diego (Vall d'Hebron Institut de Recerca) ; Universitat Autònoma de Barcelona
Reduced RHOA signalling has been shown to increase the growth/metastatic potential of colorectal tumours. However, the mechanisms of inactivation of RHOA signalling in colon cancer have not been characterised. [...]
2017 - 10.1038/bjc.2017.420
British Journal of Cancer, Vol. 118 (december 2017) , p. 106-116  
4.
8 p, 196.5 KB Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer / Sclafani, Francesco (Department of Medicine, The Royal Marsden NHS Foundation Trust) ; Brown, Gina (Department of Radiology, The Royal Marsden NHS Foundation Trust) ; Cunningham, David (Department of Medicine, The Royal Marsden NHS Foundation Trust) ; Wotherspoon, Andrew (Department of Histopathology, The Royal Marsden NHS Foundation Trust) ; Mendes, Larissa Sena Teixeira (Department of Histopathology, The Royal Marsden NHS Foundation Trust) ; Balyasnikova, Svetlana (Department of Radiology, The Royal Marsden NHS Foundation Trust) ; Evans, Jessica (Department of Radiology, The Royal Marsden NHS Foundation Trust) ; Peckitt, Clare (Clinical Research & Development, The Royal Marsden NHS Foundation Trust) ; Begum, Ruwaida (Department of Medicine, The Royal Marsden NHS Foundation Trust) ; Tait, Diana (Department of Medicine, The Royal Marsden NHS Foundation Trust) ; Tabernero Caturla, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ; Glimelius, Bengt (Department of Immunology, Genetics and Pathology, Section of Experimental and Clinical Oncology, University of Uppsala) ; Roselló, Susana (Department of Haematology and Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia) ; Thomas, Janet (Department of Medicine, The Royal Marsden NHS Foundation Trust) ; Oates, Jacqui (Department of Medicine, The Royal Marsden NHS Foundation Trust) ; Chau, Ian (Department of Medicine, The Royal Marsden NHS Foundation Trust)
Limited data exist regarding the correlation between MRI tumour regression grade (mrTRG) and pathological TRG (pTRG) in rectal cancer. mrTRG and pTRG were compared in rectal cancer patients from two phase II trials (EXPERT and EXPERT-C). [...]
2017 - 10.1038/bjc.2017.320
British Journal of Cancer, Vol. 117 (09 2017) , p. 1478-1485  
5.
12 p, 1.7 MB Ligand-dependent Hedgehog pathway activation in Rhabdomyosarcoma : the oncogenic role of the ligands / Almazán-Moga, A (Hospital Universitari Vall d'Hebron) ; Zarzosa, P (Hospital Universitari Vall d'Hebron) ; Molist, C (Hospital Universitari Vall d'Hebron) ; Velasco, Pablo (Universitat Autònoma de Barcelona. Departament de Pediatria, Obstetrícia i Ginecologia i de Medicina Preventiva i Salut Pública) ; Pyczek, J (Institute of Human Genetics, University of Goettingen) ; Simon-Keller, K (Institute of Pathology, University Medical Centre Mannheim, University of Heidelberg) ; Giralt, I (Hospital Universitari Vall d'Hebron) ; Vidal, I (LHospital Universitari Vall d'Hebron) ; Navarro, N (Hospital Universitari Vall d'Hebron) ; Segura, M F (Hospital Universitari Vall d'Hebron) ; Soriano, A (Hospital Universitari Vall d'Hebron) ; Navarro, S (Universitat de València. Departament de Patologia) ; Tirado, O M (Institut d'Investigació Biomèdica de Bellvitge (IDIBELL)) ; Ferreres, J C (Hospital Universitari Vall d'Hebron) ; Santamaria, A (Hospital Universitari Vall d'Hebron) ; Rota, R (Ospedale Pediatrico Bambino Gesù, IRCCS) ; Hahn, H (Institute of Human Genetics, University of Goettingen) ; Sánchez de Toledo, J (Hospital Universitari Vall d'Hebron) ; Roma, J (Hospital Universitari Vall d'Hebron) ; Gallego, S (Hospital Universitari Vall d'Hebron)
Rhabdomyosarcoma (RMS) is the most common type of soft tissue sarcoma in children. The Hedgehog (HH) pathway is known to develop an oncogenic role in RMS. However, the molecular mechanism that drives activation of the pathway in RMS is not well understood. [...]
2017 - 10.1038/bjc.2017.305
British Journal of Cancer, Vol. 117 (09 2017) , p. 1314-1325  
6.
10 p, 1.9 MB Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer / Codony Servat, Jordi (Institut Germans Trias i Pujol. Institut Català d'Oncologia) ; Cuatrecasas Freixas, Miriam ; Asensio, Elena (Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)) ; Montironi, Carla (Hospital Clínic) ; Martínez Cardús, Anna (Institut Germans Trias i Pujol. Institut Català d'Oncologia) ; Marín Aguilera, Mercedes (Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)) ; Horndler, Carlos (Hospital Miguel Servet) ; Martínez Balibrea, Eva (Institut Germans Trias i Pujol. Institut Català d'Oncologia) ; Rubini, Michele (Department of Experimental and Diagnostic Medicine, University of Ferrara) ; Jares, Pedro (Hospital Clínic) ; Reig, Oscar (Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)) ; Victoria, Iván (Medical Oncology Department, Hospital Clínic, Translational Genomics and Targeted Therapeutics in Solid Tumors Group, IDIBAPS, Universitat de Barcelona) ; Gaba, Lydia (Medical Oncology Department, Hospital Clínic, Translational Genomics and Targeted Therapeutics in Solid Tumors Group, IDIBAPS, Universitat de Barcelona) ; Martín Richard, Marta (Institut d'Investigació Biomèdica Sant Pau) ; Alonso, Vicente (Hospital Miguel Servet) ; Escudero, Pilar (Hospital Clínico Universitatio Lozano Blesa) ; Fernández-Martos, Carlos (Instituto Valenciano de Oncología) ; Feliu, Jaime (Hospital La Paz, CIBERONC) ; Méndez, Jose Carlos (Centro Oncológico de Galicia) ; Méndez, Miguel (Hospital de Móstoles) ; Gallego, Javier (Hospital de Elche) ; Salud, Antonieta (Hospital Arnau de Vilanova) ; Rojo, Federico (Pathology Department, Fundación Jiménez Diaz University) ; Castells, Antoni (Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)) ; Prat, Aleix (Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)) ; Rosell, Rafael (Institut Germans Trias i Pujol. Institut Català d'Oncologia) ; García-Albéniz, Xabier (Harvard T.H. Chan School of Public Health) ; Camps, Jordi (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, Fisiologia i Immunologia) ; Maurel, Joan (Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS))
Although chemotherapy is the cornerstone treatment for patients with metastatic colorectal cancer (mCRC), acquired chemoresistance is common and constitutes the main reason for treatment failure. Monoclonal antibodies against insulin-like growth factor-1 receptor (IGF-1R) have been tested in pre-treated mCRC patients, but results have been largely deceiving. [...]
2017 - 10.1038/bjc.2017.279
British Journal of Cancer, Vol. 117 (november 2017) , p. 1777-1786  
7.
12 p, 744.6 KB First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD) / Carrato, Alfredo (Instituto Ramón y Cajal de Investigación Sanitaria) ; Abad, Albert (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Massuti, Bartomeu (Hospital General de Alicante) ; Grávalos, Cristina (Hospital 12 de Octubre) ; Escudero, Pilar (Hospital Clínico Lozano Blesa) ; Longo Muñoz, Federico (Instituto Ramón y Cajal de Investigación Sanitaria) ; Manzano, José Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Gómez, Auxiliadora (Instituto Maimónides de Investigación Biomédica) ; Safont, María José (Hospital General de València) ; Gallego, Javier (Hospital General Universitario de Elche) ; García-Paredes, Beatriz (Hospital San Carlos) ; Pericay, Carles (Corporació Sanitària Parc Taulí) ; Dueñas, Rosario (Complejo Hospitalario de Jaén) ; Rivera, Fernando (Hospital Marqués de Valdecilla) ; Losa, Ferrán (Hospital General de l'Hospitalet) ; Valladares Ayerbes, Manuel (Hospital Universitario da Coruña) ; González, Encarnación (Hospital Virgen de las Nieves) ; Aranda, Enrique (Instituto Maimónides de Investigación Biomédica) ; Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) ; Universitat Autònoma de Barcelona
Abstract Background: In first-line wild-type (WT)-Kirsten rat sarcoma viral oncogene homologue (KRAS) metastatic colorectal cancer (mCRC), panitumumab (Pmab) improves outcomes when added to FOLFOX [folinic acid, 5-fluorouracil, and oxaliplatin] or FOLFIRI [folinic acid, 5-fluorouracil, and irinotecan]. [...]
2017 - 10.1016/j.ejca.2017.04.024
European Journal of Cancer, Núm. 81 (2017) , p. 191-202  
8.
9 p, 1.1 MB Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab / Fuchs, Charles S (Dana-Farber Cancer Institute. Harvard Medical School) ; Tabernero Caturla, Josep (Institut d'Oncologia de la Vall Hebron (VHIO)) ; Tomášek, Jiří (Masaryk University. Masaryk Memorial Cancer Institute (Czech Republic)) ; Chau, Ian (Royal Marsden Hospital (United Kingdom)) ; Melichar, Bohuslav (Univerzity Palackeho a Fakultni nemocnice. Onkologicka klinika (Czech Republic)) ; Safran, Howard (Brown University Oncology Research Group (USA)) ; Tehfe, Mustapha A (Centre Hospitalier de Montréal (Canada)) ; Filip, Dumitru (Spitalul Judetean de Urgenta (Romania)) ; Topuzov, Eldar (Northwest State Medical University na II Mechnikov. State Budgetary Educational Institution of Higher Professional Education (SBEIHPE). Ministry of Healthcare of the Russian Federation) ; Schlittler, Luis (Hospital da Cida de Passo Fundo (Brasil)) ; Udrea, Anghel Adrian (Medisprof SRL (Romania)) ; Campbell, William (Hospital Herrera Llerandi (Guatemala)) ; Brincat, Stephen (Sir Anthony Mamo Oncology Centre (Malta)) ; Emig, Michael (Lilly Deutschland GmbH (Germany)) ; Melemed, Symantha A (Eli Lilly and Company. Lilly Corporate Center (USA)) ; Hozak, Rebecca R (Eli Lilly and Company. Lilly Corporate Center (USA)) ; Ferry, David (Eli Lilly and Company (USA)) ; Caldwell, C William (Eli Lilly and Company. Lilly Corporate Center (USA)) ; Ajani, Jaffer A (The University of Texas MD Anderson Cancer Center (USA)) ; Universitat Autònoma de Barcelona
Angiogenesis inhibition is an important strategy for cancer treatment. Ramucirumab, a human IgG1 monoclonal antibody that targets VEGF receptor 2 (VEGFR2), inhibits VEGF-A, -C, -D binding and endothelial cell proliferation. [...]
2016 - 10.1038/bjc.2016.293
British Journal of Cancer, Vol. 115, Issue 8 (October 2016) , p. 974-982  
9.
9 p, 306.4 KB Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer / Élez Fernández, Mª Elena (Vall d'Hebron Institut d'Oncologia (VHIO)) ; Hendlisz, A. (Institut Jules Bordet (Belgium)) ; Delaunoit, T. (Centres Hospitaliers Jolimont (Belgium)) ; Sastre, J. (Hospital Universitario San Carlos) ; Cervantes, A. (Universitat de València. INCLIVA Institut d'Investigació Sanitària) ; Varea, R. (Eli Lilly and Company (Spain)) ; Chao, G. (Eli Lilly and Company (USA)) ; Wallin, J. (Eli Lilly and Company (Suècia)) ; Tabernero Caturla, Josep (Vall d'Hebron Institut d'Oncologia (VHIO)) ; Universitat Autònoma de Barcelona
This single-arm phase II study investigated the EGFR monoclonal antibody necitumumab plus modified FOLFOX6 (mFOLFOX6) in first-line treatment of locally advanced or metastatic colorectal cancer (mCRC). [...]
2016 - 10.1038/bjc.2015.480
British Journal of Cancer, Vol. 114 (February 2016) , p. 372-380  
10.
8 p, 207.5 KB Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS -mutated metastatic colorectal cancer / Macarulla Mercadé, Teresa (Vall d'Hebron Institut d'Oncologia (VHIO)) ; Cervantes, A (Universidad de Valencia. Biomedical Research Institute (INCLIVA)) ; Tabernero Caturla, Josep (Vall d'Hebron Institut d'Oncologia (VHIO)) ; Roselló, S (Universidad de Valencia. Biomedical Research Institute (INCLIVA)) ; Van Cutsem, E (University Hospitals Gasthuisberg and KU Leuven) ; Tejpar, S (University Hospitals Gasthuisberg and KU Leuven) ; Prenen, H (University Hospitals Gasthuisberg and KU Leuven) ; Martinelli, E (Second University of Naples. Department of Experimental and Clinical Medicine) ; Troiani, T (Second University of Naples. Department of Experimental and Clinical Medicine) ; Laffranchi, B (Merck Serono SA) ; Jego, V (Merck Serono SA) ; von Richter, O (Merck KGaA) ; Ciardiello, F (Second University of Naples. Department of Experimental and Clinical Medicine) ; Universitat Autònoma de Barcelona
The mitogen-activated protein kinase (MAPK) pathway has been implicated in the molecular pathogenesis of human cancers, including metastatic colorectal cancer (mCRC). This provides a rationale for the development of MAPK-targeted agents such as pimasertib. [...]
2015 - 10.1038/bjc.2015.144
British Journal of Cancer, Vol. 112 (June 2015) , p. 1874-1881  

Dipòsit Digital de Documents de la UAB : 15 registres trobats   1 - 10següent  anar al registre:
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.